WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

CMB International Securities analyst Jill Wu has maintained their bullish stance on WXIBF stock, giving a Buy rating on January 13.Stay Ahead ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

The employees at WuXi Biologics have once again shown their commitment to the local community with their fourth annual ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

WuXi Biologics employees have once again exemplified their deep-rooted commitment to the local community, delivering impactful support to St. Vincent de Paul Dundalk through their fourth annual ...

A proposed sale to a larger credit union is being put before the Dundalk District Credit Union membership for a decision in two weeks’ time. The annual general and special meeting is to take ...

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth and improved margins. Although the newsthat WuXi Bio ...

Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would limit business for Chinese biotech companies ...